Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine
Conditions
Interventions
Avacopan
Prednisone
+3 more
Locations
198
United States
Clinical Trial Site
Huntsville, Alabama, United States
Clinical Trial Site
Phoenix, Arizona, United States
Clinical Trial Site
Phoenix, Arizona, United States
Clinical Trial Site
Los Angeles, California, United States
Clinical Trial Site
Santa Monica, California, United States
Clinical Trial Site
Aurora, Colorado, United States
Start Date
March 15, 2017
Primary Completion Date
September 7, 2019
Completion Date
November 1, 2019
Last Updated
March 24, 2025
NCT07089121
NCT07151521
NCT06986018
NCT02222155
NCT02108860
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions